Trillium Therapeutics Inc. is cutting 17 jobs as part of a restructuring to focus its resources on the development of cancer treatments.
According to the company's Oct. 22 press release, the 40% reduction in staff is effective immediately, with 26 active employees remaining. The Mississauga, Ontario-based biotechnology company is looking for a partner for further development of its STING agonist program — a treatment that enhances the immune system to fight cancer tumors.
The company also plans to cut expenses through discontinuing its discovery research activities and through operational efficiencies.